噻唑烷二酮治疗与心血管疾病:利与弊
摘要
据世界卫生组织报告，目前全世界有3．46亿人患有糖尿病，其中90％为2型糖尿病（type2diabetesmellitus，T2DM）。T2DM的发病主要与胰岛索抵抗有关，并可伴胰岛素相对分泌不足。胰岛素抵抗是T2DM的主要发病机制，与肥胖、高血压和血脂异常密切相关。胰岛素抵抗发生的部位主要是外周组织（脂肪组织、骨骼肌）和肝脏。胰岛素受体或受体后缺陷导致胰岛素信号传导障碍，
出处
《实用糖尿病杂志》
2012年第4期12-14,共3页
Journal of Practical Diabetology
参考文献19
-
1Komatsu A,Node K. Effects of PPARgamma agonist on dyslip- idemia and atherosclerosis. Nihon Rinsho 2010 ;68 (2) :294 - 298.
-
2Simo R, Rodriguez A, Caveda E. Different effects of thiazo-lidinediones On cardiovascular risk in patients with type 2 diabetes mel- litus:pioglitszone versus roslglitazone. Curt Drug Saf 2010; 5 ( 3 ) : 234 - 244.
-
3Derosa G, Salvadeo S A. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional car- diovascular risk factors. Curt Clin Pharmacol 2008;3(2) :77 -84.
-
4Grey A. Thiazolidinedione - induced skeletal fragility - mecha- nisms and implications. Diabetes Obes Metab 2009; 11 ( 4 ) : 275 - 284.
-
5Pavlov T S, Imig J D, Staruschenko A. Regulation of ENaC - Mediated Sodium Reabsorption by Peroxisome Proliferator - Activated Receptors. PPAR Res 2010 ;2010:703735.
-
6KaraMedde J,Buckingham R,Starkie M,et al. Effect of various diureffc treatments on rosiglitazone - induced fluid retention. J Am Soc Nephrol 2006;17(12) :3482 -3490.
-
7Gerstein H C, Yusuf S,Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or imp '.ai/ed fasting glucose:a randomised controlled trial. Lancet 2006; 368 (9541) : 1096 - 1105.
-
8Dormandy J A Charbonncl B Ecldand D J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactivc Study ( PROspective pioglitAzonc Clinical Trial In mac- roVascular Events) :a randomised controlled trial. Lancet 2005;366 (9493) :1279 - 1289.
-
9Home P D, Pocock S J, Beck - Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination thera- py for type 2 diabetes (RECORD) :a multicentre ,randomised, open - label-trial. Lancet 2009 ;373 (9681 ) :2125 - 2135.
-
10Hugfies A D,Park C,March K,et al. A randomized placebo conolled double blind crossover study of pioglitazone on left ventricu- lar diastolic function in type 2 diabetes. Int J Cardiol 2012.
-
1刘俊江,冯凭.胰岛素受体及受体后缺陷[J].河北医药,1991,13(5):282-283.
-
2王汝昌.我是如何与糖尿病、高血压和血脂异常进行斗争的[J].药物与人,2003(10):21-21.
-
3减重手术有助于糖尿病治疗[J].糖尿病天地,2014,0(5):29-29.
-
4周亦秋,麦一峰.中重度高血压降压药物联合阿托伐他汀治疗的疗效观察[J].心脑血管病防治,2009,9(3):179-180. 被引量：1
-
5王国强.中重度高血压降压药物联合阿托伐他汀治疗的疗效观察[J].中外医学研究,2011,9(5):84-85. 被引量：1
-
6张征,邓顺有.原发性高血压血压变异性与血脂异常的相关性研究[J].现代临床医学生物工程学杂志,2005,11(4):309-310. 被引量：24
-
7刘晓丽,陆强,马春明,刘博伟,娄东辉,尹福在.秦皇岛市13-15岁人群不同空腹血糖水平心血管危险因素分析[J].国际内分泌代谢杂志,2009,29(3):175-177.
-
8陈黎.拉西地平治疗非酒精性脂肪肝合并高血压的疗效观察[J].中国医药导刊,2010,12(8):1459-1459. 被引量：1
-
9丁洁霞,厉有名.非酒精性脂肪性肝病与心血管疾病间的关系[J].中华内科杂志,2011,50(2):164-165. 被引量：4
-
10吴帆,刘宗芳,孙利强.原发性高血压患者尿酸、血脂水平及颈动脉内膜-中层厚度的临床分析[J].中国实用神经疾病杂志,2007,10(6):19-20. 被引量：2
